New data from the ongoing Open-Label Phase III Extension Study of PXT3003, the PLEO-CMT-FU trial, suggest good safety profile and continuous treatment effect of PXT3003 measured on the Overall ...
New Data from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit with PXT3003 in Patients with Charcot-Marie-Tooth Disease Type 1A After 5 Years of Total Trial Time New data from the ongoing ...
NewData from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit withPXT3003 inPatients with Charcot-Marie-Tooth Disease Type 1A After 5 Years of Total Trial Time New data from the ongoing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback